CureVac N.V. Form 6-K (Nov. 10, 2020)
Summary
A Form 6-K Report of Foreign Private Issuer furnished by CureVac N.V., Commission File Number 001-39446, for the month of November 2020. It states that on November 10, 2020, the Company issued a press release reporting detailed interim Phase 1 data for its COVID-19 vaccine candidate, CVnCoV, following topline data reported on November 2, 2020. The report states that the information in the Form 6-K, including Exhibit 99.1, shall not be deemed filed for purposes of Section 18 of the Securities Exchange Act of 1934. It is signed /s/ by Franz-Werner Haas, Chief Executive Officer.
Summary drafted by a model from the document's text below and checked by script against that text before publication. It is a navigation aid, not a reading of what the document proves. Where AI is used
Cite this document
“CureVac N.V. Form 6-K (Nov. 10, 2020).”
Original at www.sec.gov. Archived at Pandemic Darlings, https://pandemicdarlings.com/source-documents/sec-cvac-6-k-filed2020-11-10-0001104659-20-123318-9b34b97c97/
, SHA-256 9a40a9f2adba39e11e3f184d06c18a3f882b4624777cf030f3655d6901eb9188.Full text
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 Form 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 OF THE SECURITIES EXCHANGE ACT OF 1934 For the month of November 2020 Commission File Number 001-39446 CureVac N.V. Friedrich-Miescher-Strasse 15, 72076 Tübingen, Germany +49 7071 9883 0 (Address of principal executive offices) Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F: FORM 20-F x FORM 40-F ¨ Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(1): ¨ Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(7): ¨ Indicate by check mark whether the registrant by furnishing the information contained in this form is also thereby furnishing the information to the Commission pursuant to Rule 12g3-2(b) under the Securities Exchange Act of 1934: YES ¨ NO x If “Yes” is marked, indicate below the file number assigned to the registrant in connection with Rule 12g3-2(b): 82- _______ On November 10, 2020, CureVac N.V. (the “Company”) issued a press release reporting detailed interim Phase 1 data for its COVID-19 vaccine candidate, CVnCoV. The detailed interim Phase 1 data publication follows topline data reported on November 2, 2020. The press release is attached hereto as Exhibit 99.1. The information in this Form 6-K (including Exhibit 99.1) shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934 (the “Exchange Act”) or otherwise subject to the liabilities of that section, nor shall it be deemed incorporated by reference in any filing under the Securities Act of 1933 or the Exchange Act. SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized. CUREVAC N.V. By: | /s/ Franz-Werner Haas, LLD, LLM Chief Executive Officer Date: November 10, 2020 EXHIBIT INDEX EXHIBIT NO. | DESCRIPTION 99.1 | CureVac N.V. Press Release dated November 10, 2020.
File and source
- File
- SEC_CVAC_6-K_filed2020-11-10_0001104659-20-123318.htm
- Size
- 14,444 bytes
- SHA-256
- 9a40a9f2adba39e11e3f184d06c18a3f882b4624777cf030f3655d6901eb9188
- Original
- www.sec.gov